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ABSTRACT
Objective: This study is performed for investigation the chronic interaction between metformin and meloxicam from toxicological view.
Methods: Lethal dose 50 after chronic exposure assessed in mice by up and down method. Their interaction analyzed by isobolographic analysis 
indicated that both medicines exhibited synergism. Assessment of the effects of repeated chronic dosing for 3 months of both medicines also performed 
on mice. Medicines in question administered orally as therapeutic doses of metformin 14 mg/kg. Body weight (BW) (G1), meloxicam 0.2 mg/kg.BW 
(G2), and combination of both medicines (G3) while G4 assigned control and dosed DW.
Results: Both G1 and G3 showed significant p˂0.05 decrease in blood glucose and serum cholesterol levels. Meloxicam group (G3) showed statistically 
significant p˂0.05 increase in triglycerides and alanine aminotransferase (ALT), and aspartate aminotransferase (AST), while group of combination 
showed statistically significant p≤0.05 decrease in both ALT and AST. Blood urea nitrogen, uric acid, and serum creatinine showed statistically 
significant p˂0.05 increase in group of meloxicam but decrease in G3 and no changes in G1. Histopathological changes included variable lesions 
in kidney such as swelling and necrosis in renal tubules of metformin group, cortical vacuolar degeneration in renal tubules, and deterioration of 
most glomeruli in G2, while G3 showed generalized cortical necrosis of renal tubules and interstitial nephritis. Liver lesions included central venous 
congestion (VC) and perivascular lymphocytic infiltration and marked necrosis in both groups of metformin and meloxicam, while there were severe 
VC and necrosis of hepatocytes in group of combination.
Conclusion: Metformin administration with meloxicam may have beneficial important through preventing many deleterious effects of meloxicam 
after long-standing administration, but adjusting dosing regimen study might be recommended.
Keywords: Chronic, Interaction, Metformin, Meloxicam, Mice.
INTRODUCTION
More than 50 years, metformin is a worldwide prescribed antidiabetic 
[1,2], it is a biguanide derivative [3] and considered the cornerstone 
and first-line defense against type II diabetes mellitus (is a most 
common metabolic disorder) through decrease hepatic insulin 
resistance, decrease amyloid deposits, and alteration in bile acid 
metabolism [4,5]. The antihyperglycemic effect of metformin was 
dose dependent and ranged from maximum effect dose of 2000 to 
minimum 1000 mg/day in most patients [6,7]. Metformin is primarily 
absorbed from the upper gastrointestinal tract [8]. The bioavailability 
of metformin is 50% [9]. It is delivered into liver in concentration more 
higher than in the blood, finely excreted unchanged through kidney 
[10,11]. Metformin alone is a relatively safe drug clinically with only 
mild side effects including gastrointestinal disturbances (diarrhea, 
nausea, and irritation of the abdomen) [2]. Although the fact that 
the efficacy of metformin offers wide range of benefits beyond its 
blood glucose control, physicians have always been well aware of its 
adverse effects [12,13]. Meloxicam is a nonsteroidal anti-inflammatory 
(NSAID) has analgesic and antipyretic effects through  the selective 
inhibition of cyclooxygenase-2 (COX-2) [14,15]. It is recommended 
for treating rheumatoid arthritis, osteoarthritis (OA), postoperative 
pain and fever [16]. Meloxicam recommended at dose 15 mg/day in 
the treatment of rheumatoid arthritis [17], its bioavailability in mice 
is 94% after oral administration [18]. Meloxicam administration can 
result some gastrointestinal side effects such as intestinal bleeding 
and also serious cardiovascular problem, especially in persons are 
suffering from hypertension, hypercholesterolemia, and diabetes [19]. 
Liver and kidney toxicity both are adverse effects of meloxicam [20]. 
Prolonged uses of NSAIDs can produce severe adverse effects [21]. 
The ability of metformin to decrease pain severity and inflammation in 
that contributed to the pathophysiology of OA, with no serious adverse 
effects, has been carried out in many animal model studies [22,23]. 
This can be indicated that metformin can be recommended as potential 
drug to treat inflammation-related disorders [22]. Several studies have 
demonstrated that inflammation correlates with incident diabetes [24]. 
The expression of COX-2 is increased in the peripheral tissues of 
diabetic neuropathy models [25]. NSAIDs are a double-edged sword 
in that their long-term use requires caution due to their well-known 
side effects [26,27]. Extensive studies are required to validate the 
safety and evaluation of some toxicological aspects of coadministration 
of metformin and meloxicam, so we are targeted one aspect which is 




Mobic® tablet contains 15 mg meloxicam obtained from Boehringer 
Ingelheim (Germany) and Glucophage® film-coated tablet contains 
500 mg metformin from MERECK SERONO (France). Commercial Kits 
from Biosystems (Spain) used for the assessment of random blood 
glucose, cholesterol, triglycerides (TGs), alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), 
serum creatinine, and serum uric acid.
Animals
Balb-C male mice, 3 months ago, purchased from Pharmaceutical 
quality control/Ministry of Health - Iraq. They were housed under 
optimum condition of temperature 25±1°C with photoperiod followed 
dark: light cycle of 12:12 h along the period of experiment. Standard 
rodent pellet feed and drinking water provided ad libitum. They were 
remaining 2 weeks for acclimatization before any interference.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i2.29947
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Experimental design
This experiment was carried out as approved by the Scientific Committee 
in Physiology, Biochemistry, and Pharmacology Department/College 
of Veterinary Medicine, University of Baghdad, accordance to ethical 
standard of working on laboratory animals.
Dosages and dosing
All medicines that involved were calculated according to the body 
weight (BW) of animal as mg/kg.BW. They were administered with 
dose volume 0.1 ml/10 g.BW of mice by calculating and fitting all their 
concentrations for all experiments.
Median lethal dose 50 (LD50) assessment
Median LD50 of meloxicam, metformin, and their combination had 
calculated after chronic orally administration by up and down 
method [28]. Regarding to the outcome of each dose whether the 
animal was dead or alive, the doses of both medicines were decreased 
and increased by 20% respectively. LD50 for each medicine and their 
combination was calculated by the following equation:
LD50=XF+Kd
Where, Xf=the last dose
K=Constant
d=difference between doses.
Assessment of interaction of both medicines (isobolographic 
analysis)
The isobolography analysis used to determine the sort of interaction 
between and meloxicam (drug A) and metformin (drug B), if we denote 
the intercepts by A for the LD50 of drug A and by B for the LD50 of drug B, 






Where, a is the LD50 of drug A and b is of drug B when the two are 
administered together and the A and B are now the respective individual 
doses. The isobole expressed in equation above allows the assessment 
of the interactions whether are synergism, antagonism, or additive 
when actual combination doses are tested. If testing shows that the 
specified effect of a combination is achieved by a dose pair that plots as 
a point below the isobole, this means that the effect was attained with 
doses less than those on the line, a situation that denotes synergism. 
In contrast, an experiment may show that greater combination doses 
are needed to produce the specified effect, and therefore, this dose pair 
plots as a point above the isobole line denote antagonism. Dose pairs 
that experimentally lie on the line (or not significantly off the line) are 
termed additive [29].
Assessment of the effects of repeated chronic dosing of both 
medicines
A total of 20 male Balb-C mice divided equally into four groups, orally 
administered all medicines daily for 3 months and assigned as Group 1 
(G1) metformin 14 mg/kg.BW, Group 2 (G2) meloxicam 0.2 mg/kg.BW, 
and Group 3 (G3) combination of metformin plus meloxicam while the 
4th group (C) dosed distilled water and considered control group.
Blood samples collected after 3 months of dosing through heart 
puncture technique, serum obtained by centrifugation with 3000 rpm 
for 10 min for clinical chemistry. Blood glucose by spectrophotometry 
measured coupled colored complex quinoneimine [30]. Serum 
Cholesterol was measured by spectrophotometric method, briefly 
by converting cholesteryl ester to cholestenone [31]. TGs measured 
spectrophotometrically by converting them to glycerol [32]. AST 
estimated spectrophotometry through determination catalytic 
concentration of enzyme from the rate of decreased nicotinamide 
adenine dinucleotide [33]. Serum uric acid measured through coupled 
reaction which converts uric acid to allantoin in the presence of uricase 
and colored complex that can be measured by spectrophotometer 
[34,35]. BUN measured spectrophotometrically through coupled 
reaction which mediated by urease and glutamate dehydrogenase 
to form glutamate and NAD which could be measured [36,37]. 
Serum creatinine measured by reaction with picric acid in alkaline 
medium and forming colored complex which could be measured 
spectrophotometrically [38,39].
Statistical analysis was carried out by SPSS version 24.00. One- and 
two-way ANOVA employed to differentiate between means. p<0.05 was 
considered statistically significant. Least significant differences (LSD) 
used to compare between means.
RESULTS
Median LD50
The results of median LD50 of metformin, meloxicam alone, and 
their combination after chronic repeated administration in male 
mice are summarized in Table 1. Regarding to isobolography of two 
medicines metformin and meloxicam, simultaneously administrated 
in combination exhibited synergism with value of 0.77 (Diagram 1). 
Clinical observation of all mice subjected to both exposures for 24 h 
revealed restlessness or anxiety, raised tail, and grooming included 
rapid respiration, tremor, convulsions, laying down on one side, and 
finally death along 24 h of administration.
Clinical chemistry
Blood glucose, serum cholesterol, and TG
The both Groups 1 (metformin) and 3 (metformin+meloxicam) revealed 
statistically significant p<0.05 decrease in blood glucose level while 
Group 2 (meloxicam), showed non-significant change, in comparison 
with control group, Table 2. The serum cholesterol level of both 
Groups 1 and 3 showed statistically significant p<0.05 decrease while 
Table 1: LD50 of metformin, meloxicam, and their combination after chronic orally administration in male Balb‑C mice
Medicine Initial dose mg/kg.BW Last dos mg/kg.BW Number of animals Outcome Differences between doses LD50 mg/kg.BW
Metformin 1000 1400 5 OXOOX 200 1575.6
Meloxicam 400 240 5 OXXXO 80 303
Metf+melox 755.5+171.5 755.5+171.5 5 XOXOX 200 metf, 80 melox 615.3+115.42
K of metformin=0.878, K of meloxicam=1.288, K of combination=−0.701. LD50: Lethal dose 50, BW: Body weight
Diagram 1: Isobolographic of combination lethal dose 50 
of metformin plus meloxicam in mice after orally chronic 
administration
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Group 2 did not show any significant change in comparison with the 
control group, Table 2. The only serum TG level of Group 2 (meloxicam) 
exhibited statistically significant p<0.05 increase, while other treated 
Groups 1 and 2 did not do when compared to control group, Table 2.
ALT and AST
The animals of treated group two (meloxicam) showed statistically 
significant p<0.05 increase in both ALT and AST serum activity in 
comparison with both treated Groups 1 and 3 (metformin, combination) 
and control group. Furthermore, Group 3 revealed statistically 
significant p<0.05 increase in both ALT and AST when compared to G1 
and control group, while Group 1 did not show any significant changes 
in both enzymes activity in comparison with the control, Table 3.
Serum uric acid, creatinine, and BUN
The animals of Group 2 (meloxicam) revealed statistically significant 
p<0.05 increase in serum uric acid, creatinine, and BUN when 
compared to other treated groups and control, while the animals of 
Group 1 (metformin) showed non-significant changes in all these 
parameters in comparison with the control one. Group 3 (combination) 
showed statistically significant p<0.05 decrease in uric acid, increase 
in serum creatinine in comparison to the control group, and there is no 
significant change in BUN, Table 4.
BW
There were statistically significant p<0.05 differences in BW between 
all treated groups before treatment while after 3 months, the BWs 
revealed no significant differences. However, the results of BW within 
groups showed statistically significant p<0.05 decrease after 3 months 
of treatment in comparison with their pretreatment BWs, Table 5.
Histopathology
Kidney
The renal sections of G1 (metformin) showed acute generalize cortical 
cellular swelling with necrosis of renal tubules, and medullary vacuolar 
degeneration (Vd) and necrosis of tubules (Figs. 1 and 2). The renal 
histopathological lesions of G2 (meloxicam) were included severe 
cortical Vd of proximal and distal renal tubules with deterioration of 
most glomeruli (Fig. 3); however, the renal medulla showed variable 
degrees of degenerative changes of collecting tubules with cast 
formation and necrosis (Fig. 4), while G3 (metformin plus meloxicam) 
revealed generalize cortical necrosis of renal tubules and acute cellular 
swelling and interstitial nephritis in medulla (Fig. 5).
Liver
Liver section of both G1 and G2 showed similar histopathological lesions 
which represented by central venous congestion (VC), perivascular 
lymphocytic infiltration with marked necrosis of hepatocyte cords 
(Fig. 6). The lesion which was observed in liver of G3 included severe 
central VC, disarranged of hepatocyte cords, and necrosis (Figs.7 and 8).
DISCUSSION
Drug interaction is a status when two or more than one medicine 
are taking simultaneously for caring certain disease. Mostly, in 
clinical application, physicians prescribe more than one medicine, 
so these medicines may interfere between each other through 
pharmacokinetic pathways or pharmacodynamically. Both 
pharmacological pathways consequence several sorts of interactions 
whether are beneficial or non-beneficial. The beneficial one is mostly 
therapeutically desirable while the non-beneficial one may be 
considered toxicological interaction and may harmful to the patient. 
Here, we conducted our study to review the interaction between 
hypoglycemic medicine metformin and analgesic, anti-inflammatory 
one meloxicam from some toxicological views, which included 
evaluation chronic interaction trough measuring LD50 of both two 
medicines when administrated separately and in combination, also 
some liver and kidney functions biochemical markers use as tools 
for this purpose. In such study, in mice, both medicines showed 
synergism and antagonism sort of interaction after acute and 
subchronic administration, respectively [40].
We thought the decrease in blood glucose level in the animals treated 
with metformin alone and in combination is a logical consequence 
due to hypoglycemic effect of metformin, meloxicam did not influence 
the hypoglycemic effect of metformin, and this is also evident by not 
affecting the level of blood glucose level in the mice that treated with 
meloxicam alone. It is noteworthy that the remaining 50% of metformin, 
which is unabsorbed, accumulates in the gut mucosa of the distal small 
intestine at concentrations 30–300-fold greater than in the plasma [41]. 
Moreover, ultimately is eliminated with feces. However, in humans, 
gut effect of metformin remains largely obscure, although several 
Table 2: Glucose mg/dl, cholesterol mg/dl, and TG mg/dl
Group Glucose M±SE Cholesterol M±SE TG M±SE
G1 (metformin) 49.00±4.99C 46.00±1.81B 74.00±3.03B
G2 (meloxicam) 141.60±4.26A 75.60±1.96A 106.00±2.91A
G3 (metformin+meloxicam) 105.00±2.73B 46.40±3.90B 74.20±1.77B
G4 (DW) control 144.60±3.04A 94.60±19.04A 79.60±13.03B
LSD 9.23 24.22 17.05
Capital letters denote statistically significant differences p<0.05 between groups. LSD: Least significant differences
Table 3: ALT and AST (U/L)
Group ALT M±SE AST M±SE
G1 (metformin) 38.60±3.48C 94.60±4.54C
G2 (meloxicam) 88.00±4.27A 167.80±9.02A
G3 (metformin+meloxicam) 57.00±8.22B 129.64±10.02B
G4 (DW) control 34.20±3.73C 100.20±7.67C
LSD 13.06 19.97
Capital letters denote statistically significant differences p<0.05 between 
groups. ALT: Alanine aminotransferase, AST: Aspartate aminotransferase. 
LSD: Least significant differences
Fig. 1: Section of renal cortex (G1) shows cellular swelling 
(arrows) and necrosis of renal tubules (N). Hematoxylin and 
eosin stain ×100
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proposals have been suggested from animal experiments including 
delayed intestinal glucose absorption [2]. Metformin non-competitively 
inhibits the redox shuttle enzyme mitochondrial glycerophosphate 
dehydrogenase, resulting in an altered hepatocellular redox state, 
reduced conversion of lactate and glycerol to glucose, and decreased 
hepatic gluconeogenesis [42]. A certain study has demonstrated that 
the gut is the primary site of action [43].
Hyperlipidemia is an elevation of lipids in the blood. These include 
cholesterol, cholesterol esters, phospholipids, and TGs [44]. 
Measurement of TG and total blood cholesterol is important in the 
diagnosis and management of hyperlipidemia, hypertriglyceridemia 
refers to high TG levels in the blood [45,46]. Acute pancreatitis is an 
Table 4: Uric acid, creatinine, and BUN
Group Uric acid Creatinine BUN
M±SE M±SE M±SE
G1 (metformin) 6.30±0.43 BC 0.42±0.03C 23.00±3.27B
G2 (Meloxicam) 14.80±1.71A 1.64±0.15A 40.40±3.31A
G3 (metformin+meloxicam) 5.28±0.28C 1.00±0.27B 23.60±2.11B
G4 (DW) control 9.82±2.50B 0.34±0.05C 24.80±1.49B
LSD 3.8 0.13 6.57
Capital letters denote statistically significant differences p<0.05 between groups. LSD: Least significant differences, BUN: Blood urea nitrogen
Table 5: BW/kg
Group Pretreatment M±SE After 3 months of treatment M±SE
G1 (metformin) 27.05±1.26 B a 23.33±0.84 A b
G2 (meloxicam) 29.25±0.94 B a 23.33±0.98 A b
G3 (metformin+meloxicam) 32.50±6.44 A a 23.66±0.95 A b
LSD=2.48. Capital letters denote statistically significant differencesp<0.05 between groups. Small letters denote statistically significant differences p<0.05 within groups. 
LSD: Least significant differences, BW: Body weight
Fig. 2: Section of renal medulla (G1) shows vacuolar degeneration 
and necrosis of tubules. Hematoxylin and eosin stain ×400
Fig. 3: Section of renal cortex (G2) shows vacuolar degeneration 
and necrosis of collecting tubules (N). Hematoxylin and eosin 
stain ×400
Fig. 4: Section of renal medulla (G2) shows cast formation (C), 
vacuolar degeneration, and necrosis of collecting tubules (N). 
Hematoxylin and eosin stain ×400
Fig. 5: Section of kidney (G3) shows cortical region (Cr), 
necrosis (N), medulla region (Me) interstitial nephritis (In), and 
acute cellular swelling (arrows). Hematoxylin and eosin stain ×400
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inflammatory process of the pancreas with varying involvement of 
other regional tissues or remote organ systems [47]. Very high TG levels 
also increase the risk of acute pancreatitis [48]. Chronic pancreatitis 
may develop as a result of acute pancreatitis, chronic pancreatitis can 
lead to diabetes or pancreatic cancer and unexplained weight loss 
may occur from a lack of pancreatic enzymes hindering digestion. We 
thought this is one of the relied perceptions of weight loss in mice of all 
experimental groups (Table 5), and the suspicion that meloxicam dosing 
is underlying in pancreatitis in mice especially of G2. However, up to 2% 
of acute pancreatitis cases may be caused by drugs [49,50]. Potential 
mechanisms of drug-induced pancreatitis include hypersensitivity 
(onset after 4–8 weeks of use), accumulation of a toxic metabolite 
(onset after several months of use), and hypertriglyceridemia (onset 
after several months of use) [47]. Meloxicam is one of the drugs which 
is implicated in ≤10 cases of pancreatitis [49].
It has become increasingly apparent that the liver and kidney are also 
important targets for untoward clinical events of NSAIDs [51,52]. In 
general, the clinical manifestations of NSAID toxicity in liver can present 
as two distinct forms, mild hepatic changes and the more significant 
hepatic injuries. The mild hepatic changes, which are relatively frequent 
and usually observed in Phase III clinical trial before marketing, are 
evident as minor increases in liver enzymes in the plasma [53]. This 
is in agreement with our finding when we found mild increasing 
ALT activity in mice exposed to meloxicam for 3 months, Table 3; 
consequently, meloxicam caused mild hepatic change. However, orally 
administration both meloxicam and metformin to mice for 2 months 
had had no significant changes in serum TG, ALT, AST activity, and 
cholesterol [40]. On the other hand, the latter form of liver injury is 
rare but can have fatal outcome. In general, the mechanism is thought 
to be an idiosyncratic reaction (immunologic or metabolic) rather 
than an intrinsic toxicity of the agent. Although hepatotoxicity has 
been attributed to the entire therapeutic class of NSAIDs, the rates and 
types of injury often vary within and between chemical classes [54]. 
We thought that the mild hepatic histological lesion which represented 
by central VC, perivascular lymphocytic infiltration with necrosis of 
hepatocyte cords in G3 mice (exposed to meloxicam) is not enough to 
being hepatotoxic. Generally, liver is highly regenerative organ which 
can overcome some injuries. One of the typical complications induced 
by COX-2 inhibitors was found, such as cardiovascular complications 
[54]. Somewhat, when we found increasing in AST activity in mice 
exposed to meloxicam only (Table 3), this is considered one of the 
several biomarkers referring cardiotoxicity. In a study by Al-Rekabi et al. 
[55], it was shown that administration of 0.2 and 0.6 mg/kg meloxicam 
to rats increased aspartate aminotransferase level.
COX-2 is also expressed constitutively in a few organs including the 
brain and kidney [56]. Basal levels of COX-2 have been located in 
the macula densa, thick ascending limbs, and papillary interstitial 
cells of rats and in the glomerular podocytes [57]. Despite extensive 
studies on the toxicity of NSAIDs on various organs, the mechanism 
of NSAID-induced renal injury has not been completely clarified said 
[53]. Obviously, the elevations in serum UA, creatinine, and BUN are 
clinically biomarker for renal impairment or toxicity; this is specifically 
proved in group received meloxicam only in our recent study, Table 4. 
Enzymatic substance determination in blood and sermi-optical test 
after Warburb. The thought  that kidney susceptibility to any toxic 
injury is partially due to its  high blood flow. Kidneys receive about 20–
25% of the resting cardiac output, and hence, any drug in the systemic 
circulation will be delivered to this organ in relatively high amounts. 
The processes involved in forming concentrated urine also serve to 
concentrate potential toxicants in the tubular fluid [57]. In addition to 
the increase in the indices of renal toxicity due to the chronic exposure 
to meloxicam, there are also the severe histological changes observed 
in the kidneys of these mice, which were represented by severe cortical 
Vd of proximal and distal renal tubules with deterioration of most 
glomeruli. Since COX-2 is important in renal prostaglandin I2 synthesis, 
it implies that COX-2-selective inhibitors would have the same effects 
on renal function as conventional NSAIDs. Indeed, two COX-2-selective 
inhibitors, celecoxib and rofecoxib, have been shown to cause sodium 
retention and decrease glomerular filtration rate to a similar extent as 
non-selective NSAIDs [58].
Fig. 6: Section of liver lobule shows, central venous congestion, 
lymphocytes infiltration (arrow), and necrosis (N). H and E 
stain ×400
Fig. 7: Section of liver (G3) shows congestion of central vein (Cvc). 
Hematoxylin and eosin stain ×100
Fig. 8: Section of liver (G3) shows narcosis of hepatocytes (arrows) 
and marked disarrangement of hepatic hexagon. Hematoxylin 
and eosin stain ×100
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Despite meloxicam is one COX-2-selective NSAIDs do not seem to spare 
the kidneys from adverse side effects. In a certain case report, a 56-year-
old male who kept under metformin 750 mg daily for long period, BUN, 
serum creatinine, and liver enzymes were in normal limit [59].
CONCLUSION
Metformin administration with meloxicam have may beneficial 
important through preventing many deleterious effects of meloxicam 
after long-standing administration, but adjusting dosing regimen study 
might be recommended.
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